Spencer Farr, Ph.D. studied engineering and genetics at UC. Berkeley. He earned a Ph.D. in Molecular and Cell Biology at the University of New Mexico School of Medicine and the Institut Jacques Monod in Paris France, where he was a Fulbright Scholar. Spencer was an NIH post-doctoral fellow in Bruce Ames lab at UC. Berkeley and then joined the faculties of Harvard and MIT in molecular toxicology. He was the founder and CEO of Xenometrix Inc., Phase-1 Molecular Toxicology Inc., and Vista Therapeutics, Inc. Vista Therapeutics applies proprietary nanotechnology to the field of clinical medicine and drug development.